Rebuilding Healthcare Supply Chains in Africa: Lessons from COVID-19 and the Road Ahead

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Rebuilding Healthcare Supply Chains in Africa: Lessons from COVID-19 and the Road Ahead

Ascolta gratuitamente

Vedi i dettagli del titolo

Healthcare systems around the world are facing growing pressure from supply chain disruption, rising costs, regulatory complexity, and persistent medicine shortages. The COVID-19 pandemic exposed just how vulnerable global pharmaceutical and healthcare networks can be, forcing industry leaders to rethink resilience, localisation, and long-term sustainability. At the same time, emerging technologies such as artificial intelligence are beginning to transform how healthcare organisations manage regulation, logistics, and patient access at scale.In this episode of Chain Reaction, host Trisha Pillay sits down with healthcare strategist, clinician, and Vicore Health CEO Émile Malan to examine the mounting pressures reshaping pharmaceutical supply chains across Africa. From the vulnerabilities exposed during the COVID-19 pandemic to the emergence of AI-driven regulatory systems, the conversation explores the critical challenges, structural gaps, and technological opportunities likely to define the future of healthcare delivery on the continent over the next decade.COVID-19 wake-up call for healthcare supply chainsFew events have stress-tested global healthcare supply chains quite like the COVID-19 pandemic. When the world shut down in early 2020, the cracks in pharmaceutical distribution networks became impossible to ignore, especially across Africa."Supply chains for medicines are heavily dependent on China and India," Malan explains. When those pipelines stalled, African healthcare systems felt the impact acutely. The continent's reliance on imported active pharmaceutical ingredients (APIs) and finished products left millions of people exposed at the worst possible time.The pandemic revealed more than just import dependency. It exposed deep regulatory bottlenecks that prevented locally manufactured vaccines, including those produced by South Africa's own Aspen Pharmacare, from reaching neighbouring countries in time. Manufacturing capacity existed. The system failed at the approval stage.For healthcare professionals, policymakers, and pharmaceutical executives, the lesson was stark: regional manufacturing capability means nothing without the regulatory infrastructure to move products across borders efficiently.Africa's manufacturing gapTo understand the scale of the challenge, consider this: Africa carries approximately 25 per cent of the world's disease burden, yet manufactures only around 3 per cent of the world's health products. That structural gap between need and local production sits at the heart of every supply chain conversation on the continent.Malan is candid about the economics. Building a pharmaceutical manufacturing facility requires significant capital investment, strong government commitment, and reliable demand forecasting. Without these foundations, investors hesitate. "You need strong government commitment. You need them to honour their commitments," he notes. In a continent of 54 sovereign nations, aligning those commitments across borders is a formidable coordination challenge.The scale problem compounds further when compared to global competitors. India and China have refined pharmaceutical manufacturing to serve domestic markets of over a billion people each, achieving unit costs that African manufacturers, working at a fraction of that scale, simply cannot yet match on finished products alone.Regional supply resilienceDespite these hurdles, momentum is building. The African Free Trade Initiative and the African Medicines Agency (AMA) are working toward a more harmonised regulatory landscape, one that could eventually enable medicines approved in one African market to move freely into others. For healthcare supply chain resilience, this kind of regulatory convergence is not a nice-to-have. It is essential.Malan points to the maturity gap in African regulatory bodies as a critical area for intervention. Of the continent's 54 national regulators, only 9 have achieved maturity level 3 in the World Health Organisation's assessment framework, meaning the vast majority operate with limited systems, constrained human capacity, and underdeveloped processes. Addressing this gap is where technology enters the picture.AI and Digital HealthcareThe transformative potential of artificial intelligence in healthcare operations is no longer theoretical. Malan's own organisation is actively deploying AI and large language model (LLM) technologies within highly regulated pharmaceutical workflows, and the results are striking."AI can boost productivity by a factor of five in healthcare processes," he says. In practical terms, that means one person today can deliver the output that five people produced just two years ago. In a region where regulatory and healthcare workforce capacity is chronically strained, this is not a marginal improvement; it is a structural shift.The key, Malan emphasises, is responsible deployment: the right human expertise in the lead, with AI augmenting rather than replacing ...

Ancora nessuna recensione